Evidence map›Paper›PMID 23306083›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2013

Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate.

Angela K Moss, Sulaiman R Hamarneh, Mussa M Rafat Mohamed, Sundaram Ramasamy, Halim Yammine, Palak Patel, Kanakaraju Kaliannan, Sayeda N Alam, Nur Muhammad, Omeed Moaven and 8 more

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Alkaline phosphatase treatment of acute kidney injury-an update.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Review
  3. Article
  4. Article
  5. Current status ofRSC advances · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Angela K MossDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. akmoss@partners.org
Sulaiman R Hamarneh
Mussa M Rafat Mohamed
Sundaram Ramasamy
Halim Yammine
Palak Patel
Kanakaraju Kaliannan
Sayeda N Alam
Nur Muhammad
Omeed Moaven
Abeba Teshager
Nondita S Malo
Sonoko Narisawa
José Luis Millán
H Shaw Warren
Elizabeth Hohmann
Madhu S Malo
Richard A Hodin
Massachusetts General Hospital · USHarvard University · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Elizabeth Austen Lawson, Takara Leah Stanley · 1994 to 2026
$31.6M
MOLECULAR PATHOGENESIS/TREATMENT OF HYPOPHOSPHATASIAR01DE012889 · NIDCR · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI MILLAN, JOSE LUIS · 1999 to 2020
$9.2M
Mechanisms of initiation of skeletal mineralizationR01AR053102 · NIAMS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI MILLAN, JOSE LUIS · 2006 to 2015
$3.8M
ADVANCED TRAINING IN SURGICAL ONCOLOGYT32CA009535 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUENO, RAPHAEL · 1985 to 2015
$3.5M
THYROID HORMONE AND THE GUTR01DK050623 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI HODIN, RICHARD A. · 1996 to 2010
$3.4M
MOLECULAR MECHANISMS OF INTESTINAL ATROPHY/HYPERPLASIAR01DK047186 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI HODIN, RICHARD A. · 2000 to 2011
$3.4M
Mouse model for sepsisR01AI059010 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WARREN, H SHAW · 2005 to 2009
$1.9M
NCI NIH HHS T32 CA-009535NIAID NIH HHS AI-059010NIAMS NIH HHS R01 AR053102NIDCR NIH HHS R01 DE012889NIDDK NIH HHS P30 DK040561NIDDK NIH HHS P30 DK043351NIDDK NIH HHS R01 DK-047186NIDDK NIH HHS R01 DK-050623
6 · The paper itself

Abstract

Uridine diphosphate (UDP) is a proinflammatory nucleotide implicated in inflammatory bowel disease. Intestinal alkaline phosphatase (IAP) is a gut mucosal defense factor capable of inhibiting intestinal inflammation. We used the malachite green assay to show that IAP dephosphorylates UDP. To study the anti-inflammatory effect of IAP, UDP or other proinflammatory ligands (LPS, flagellin, Pam3Cys, or TNF-α) in the presence or absence of IAP were applied to cell cultures, and IL-8 was measured. UDP caused dose-dependent increase in IL-8 release by immune cells and two gut epithelial cell lines, and IAP treatment abrogated IL-8 release. Costimulation with UDP and other inflammatory ligands resulted in a synergistic increase in IL-8 release, which was prevented by IAP treatment. In vivo, UDP in the presence or absence of IAP was instilled into a small intestinal loop model in wild-type and IAP-knockout mice. Luminal contents were applied to cell culture, and cytokine levels were measured in culture supernatant and intestinal tissue. UDP-treated luminal contents induced more inflammation on target cells, with a greater inflammatory response to contents from IAP-KO mice treated with UDP than from WT mice. Additionally, UDP treatment increased TNF-α levels in intestinal tissue of IAP-KO mice, and cotreatment with IAP reduced inflammation to control levels. Taken together, these studies show that IAP prevents inflammation caused by UDP alone and in combination with other ligands, and the anti-inflammatory effect of IAP against UDP persists in mouse small intestine. The benefits of IAP in intestinal disease may be partly due to inhibition of the proinflammatory activity of UDP.

Indexed as

Disease Models, AnimalInflammation MediatorsInflammatory Bowel DiseasesAlkaline PhosphataseAnimalsBacterial ProteinsCells, CulturedHumansInterleukin-8Intestinal MucosaIntestine, SmallLipopolysaccharidesMiceMice, KnockoutReceptors, Purinergic P2Uridine DiphosphateAlkaline PhosphataseBacterial ProteinsInflammation MediatorsInterleukin-8Lipopolysaccharidespurinoceptor P2Y6Receptors, Purinergic P2Uridine Diphosphate

Identifiers

PMID23306083
PMCPMC3602687
OpenAlexW2228584869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.